ALK and lung cancer: Currently, the treatment of lung cancer has been revolutionized by major advances in large-scale molecular profiling of lung tumors unveiling an increasing list of oncogenic drivers exploited as therapeutic targets (e.g., epidermal growth factor receptor [EGFR], vraf murine sarcoma viral oncogene homolog BE [BRAF], rearrangements in anaplastic lymphoma kinase [ALK], proto-oncogene tyrosine-protein kinase ROS1, and neurotrophic receptor tyrosine kinase [NTRK]).